Breaking News, Collaborations & Alliances

Chime Biologics and Waterstone Partner to Advance ADC Development

Will offer a comprehensive solution to ADC developers for IND-enabling and clinical studies.

Author Image

By: Charlie Sternberg

Associate Editor

Chime Biologics, a global CDMO, and Waterstone have entered a strategic partnership aimed at providing integrated services for the Antibody-Drug Conjugate (ADC) industry worldwide.   Through this collaboration, Chime Biologics and Waterstone will offer a comprehensive solution to ADC developers for IND-enabling and clinical studies. Leveraging its CMC expertise in biologics, Chime Biologics will manage Antibody Intermediate, ADC Drug Substance and Drug Product process development and cGMP manu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters